The EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Gilead’s COVID-19 treatment remdesivir – making it the first drug of its kind to be given such a recommendation in the EU.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,